论文部分内容阅读
青光眼是最常见的致盲性眼病之一，其发病机制尚不完全明确，但已知眼压升高是导致疾病进展的持续危险因素。目前对于减缓青光眼进展唯一有效的治疗干预措施是降低眼压。一般来说，视网膜神经节细胞不可再生，所以视神经保护尤为重要。近年来随着对青光眼发病机制研究的深入，药物研发水平的提高，新型抗青光眼药物逐渐问市。本文将对新型抗青光眼药物的机制、有效性、安全性以及尚在研究中的新靶点进行综述。“,”Glaucoma is one of the most common blinding eye diseases.The pathogenesis is not completely clear, but it is known that increased intraocular pressure is a continuous risk factor for disease progression.At present, the only effective therapeutic intervention to slow the progression of glaucoma is to reduce intraocular pressure.In general, retinal ganglion cells are not regenerative, so optic nerve protection is also particularly important.In recent years, with the in-depth study of the pathogenesis of glaucoma and the improvement of drug research and development, new anti-glaucoma drugs have gradually come to the market.This article will review the mechanism, effectiveness, and safety of new anti-glaucoma drugs, as well as new targets still under research.